Vaccine‐Induced Th1‐Type Responses are Dominant over Th2‐Type Responses in the Short Term whereas Pre‐existing Th2 Responses are Dominant in the Longer Term

The effect of adjuvant on induction of human papillomavirus type 16 E7 protein‐specific cytotoxic T lymphocytes (CTL) and immunoglobulin G (IgG)2a antibody was studied in C57BL/6 J mice immunized with various adjuvants and E7 protein. Quil‐A adjuvant, but not complete Freund's adjuvant (CFA) or...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of immunology 1998-05, Vol.47 (5), p.459-465
Main Authors: Fernando, G J, Stewart, T J, Tindle, R W, Frazer, I H
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - pharmacology
AIDS/HIV
Animals
Antibody Formation - drug effects
Antibody Formation - immunology
Dose-Response Relationship, Immunologic
Female
Immunity, Cellular - drug effects
Immunity, Cellular - immunology
Immunotherapy
Mice
Mice, Inbred C57BL
Oncogene Proteins, Viral - administration & dosage
Oncogene Proteins, Viral - immunology
Papillomavirus E7 Proteins
Papillomavirus Infections - therapy
Th1 Cells - drug effects
Th1 Cells - immunology
Th2 Cells - drug effects
Th2 Cells - immunology
Time Factors
Tumor Virus Infections - therapy
Vaccination
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The effect of adjuvant on induction of human papillomavirus type 16 E7 protein‐specific cytotoxic T lymphocytes (CTL) and immunoglobulin G (IgG)2a antibody was studied in C57BL/6 J mice immunized with various adjuvants and E7 protein. Quil‐A adjuvant, but not complete Freund's adjuvant (CFA) or Algammulin, induced a T‐helper 1 (Th1)‐type response to E7, which was characterized by CTL activity against a tumour cell line transfected with E7 protein and by E7‐specific IgG2a. All tested adjuvants elicited comparable levels of E7‐specific IgG1. The longest duration and greatest magnitude of CTL response was seen following two immunizations with the highest dose of E7 and Quil‐A. Simultaneous immunization with a Th1 and a T helper 2 (Th2)‐promoting adjuvant gave a Th1‐type response. However, E7 and Quil‐A were unable to induce a Th1‐type response (as measured by the inability to generate anti‐E7 IgG2a antibody) in animals with a pre‐existing Th2‐type response to E7. These results suggest that saponin adjuvants may be suitable for immunotherapy in humans where a Th1‐type response is sought, provided that there is no pre‐existing Th2‐type response to the antigen.
ISSN:0300-9475
1365-3083
DOI:10.1046/j.1365-3083.1998.00327.x